LUNG CANCER, NONSMALL CELL
Clinical trials for LUNG CANCER, NONSMALL CELL explained in plain language.
Never miss a new study
Get alerted when new LUNG CANCER, NONSMALL CELL trials appear
Sign up with your email to follow new studies for LUNG CANCER, NONSMALL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple drug cocktail shows promise against tough lung cancer
Disease control OngoingThis study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first fi…
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Scientists probe how lung cancer outsmarts key drugs
Knowledge-focused OngoingThis study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find w…
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 23, 2026 20:48 UTC
-
Can a simple blood test predict lung Cancer's next move?
Knowledge-focused OngoingThis study looks at 23 people with advanced non-small cell lung cancer who have finished at least 20 months of immunotherapy. Researchers will collect blood and tissue samples to see if certain immune markers can predict whether the cancer will come back within 6 months. The goal…
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:57 UTC
-
New study tracks risks of combining lung cancer treatments
Knowledge-focused OngoingThis study looks at side effects in people with stage IV non-small cell lung cancer who get both immunotherapy (nivolumab or pembrolizumab) and palliative radiation to the chest. It follows 12 patients for up to 2 years to track radiation-related toxicities, survival, and quality…
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:50 UTC